Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation
- PMID: 347855
- DOI: 10.1530/acta.0.0870855
Serum lipids and lipoproteins during treatment with oral contraceptives containing natural and synthetic oestrogens. A controlled double-blind investigation
Abstract
PIP: Increases in serum triglycerides, cholesterol and pre-beta- and beta-lipoproteins have been considered as significant pathogenic factors regarding the possible thrombotic side effect of treatment with oral contraceptives (OCs) of the combined type containing synthetic estrogen. To investigate the influence of natural estrogen (estradiol-17beta + estriolnorethisterone acetate) vs. synthetic oestrogen (ethinyl estradiol-norethisterone acetate) on serum lipids and lipoproteins in young women compared with independent and individual controls, as controlled doubleblind investigation was performed in 33 women in a total material and 18 women in a selected group. The significant changes were: quantitative increases in serum triglycerides (p , .001) and beta-lipoproteins (p , .01) during treatment with synthetic oestrogen; no such change was observed in subjects on natural oestrogen, which was found to decrease serum cholesterol (p , .05), phospholipids (p , .05), and alpha-lipoprotein (p , .05). Quantitative estimation of serum lipoproteins was found to be more valuable than the relative estimation by electrophoresis. It is concluded that OCs containing natural estrogens induce less significant and, qualitatively, more benign changes in serum lipids and lipoproteins than preparations containing a synthetic estrogen do.
Similar articles
-
Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.Fertil Steril. 1978 Nov;30(5):522-33. doi: 10.1016/s0015-0282(16)43632-0. Fertil Steril. 1978. PMID: 214353
-
Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.N Engl J Med. 1983 Apr 14;308(15):862-7. doi: 10.1056/NEJM198304143081502. N Engl J Med. 1983. PMID: 6572785
-
A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception.Contraception. 1980 May;21(5):445-59. doi: 10.1016/0010-7824(80)90010-4. Contraception. 1980. PMID: 7428356 Clinical Trial.
-
Contraception for women with diabetes: an update.Baillieres Clin Obstet Gynaecol. 1991 Jun;5(2):493-503. doi: 10.1016/s0950-3552(05)80109-9. Baillieres Clin Obstet Gynaecol. 1991. PMID: 1954724 Review.
-
Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.Am J Obstet Gynecol. 1994 May;170(5 Pt 2):1556-61. doi: 10.1016/s0002-9378(94)05019-2. Am J Obstet Gynecol. 1994. PMID: 8178906 Review.
Cited by
-
Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells.J Clin Invest. 1981 Jun;67(6):1650-8. doi: 10.1172/jci110201. J Clin Invest. 1981. PMID: 7240413 Free PMC article.
-
An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.Gynecol Endocrinol. 2012 May;28(5):400-8. doi: 10.3109/09513590.2012.662547. Epub 2012 Apr 2. Gynecol Endocrinol. 2012. PMID: 22468839 Free PMC article. Review.
-
Effects of exercise on the serum concentrations of FSH, LH, progesterone, and estradiol.Eur J Appl Physiol Occup Physiol. 1979 Sep;42(1):15-23. doi: 10.1007/BF00421100. Eur J Appl Physiol Occup Physiol. 1979. PMID: 499193